AVEO Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
AVEO Pharmaceuticals, Inc.‘s stocks are currently a part of 57 hedge funds’ portfolios, which represents 41.09% of the total amount of its stocks outstanding. This makes up a total of 14.12M shares of AVEO Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -8.39% or -1.29M shares fewer. As for the holding position changes, 22.81% (13) of current hedge fund investors increased the number of shares held, 26.32% (15) of current holders sold a part of the shares held, and 14.04% (8) closed the holdings completely. 11 hedge funds are new holders of AVEO Pharmaceuticals, Inc. stock in Q1 2022, it is 19.3% of total holders.
Hedge funds holding AVEO Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 48 |
|---|---|
| Q3 2017 | 56 |
| Q4 2017 | 81 |
| Q1 2018 | 84 |
| Q2 2018 | 88 |
| Q3 2018 | 96 |
| Q4 2018 | 95 |
| Q1 2019 | 80 |
| Q2 2019 | 70 |
| Q3 2019 | 58 |
| Q4 2019 | 57 |
| Q1 2020 | 30 |
| Q2 2020 | 63 |
| Q3 2020 | 62 |
| Q4 2020 | 64 |
| Q1 2021 | 74 |
| Q2 2021 | 62 |
| Q3 2021 | 52 |
| Q4 2021 | 54 |
| Q1 2022 | 57 |
Hedge funds changes in AVEO Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 20 | 8 | 9 | 13 | -2 |
|---|---|---|---|---|---|
| Q3 2017 | 19 | 17 | 12 | 10 | -2 |
| Q4 2017 | 33 | 21 | 12 | 8 | 7 |
| Q1 2018 | 18 | 24 | 22 | 13 | 7 |
| Q2 2018 | 31 | 29 | 12 | 25 | -9 |
| Q3 2018 | 22 | 35 | 17 | 15 | 7 |
| Q4 2018 | 20 | 30 | 22 | 20 | 3 |
| Q1 2019 | 10 | 22 | 23 | 24 | 1 |
| Q2 2019 | 17 | 16 | 21 | 26 | -10 |
| Q3 2019 | 8 | 15 | 15 | 19 | 1 |
| Q4 2019 | 12 | 12 | 14 | 12 | 7 |
| Q1 2020 | 28 | 1 | 1 | 54 | -54 |
| Q2 2020 | 37 | 14 | 5 | 5 | 2 |
| Q3 2020 | 13 | 22 | 15 | 14 | -2 |
| Q4 2020 | 15 | 24 | 9 | 13 | 3 |
| Q1 2021 | 19 | 21 | 19 | 9 | 6 |
| Q2 2021 | 15 | 14 | 23 | 27 | -17 |
| Q3 2021 | 12 | 14 | 14 | 22 | -10 |
| Q4 2021 | 10 | 14 | 16 | 8 | 6 |
| Q1 2022 | 11 | 13 | 15 | 8 | 10 |
Hedge funds changes in AVEO Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 1,604,000 | 88,000 |
|---|---|---|
| Q3 2017 | 6,609,000 | 1,513,000 |
| Q4 2017 | 5,911,000 | 1,334,000 |
| Q1 2018 | 10,478,000 | 1,439,000 |
| Q2 2018 | 13,684,000 | 2,098,000 |
| Q3 2018 | 21,673,000 | 5,637,000 |
| Q4 2018 | 12,317,000 | 3,635,000 |
| Q1 2019 | 3,860,000 | 1,367,000 |
| Q2 2019 | 3,101,000 | 1,828,000 |
| Q3 2019 | 3,189,000 | 2,086,000 |
| Q4 2019 | 2,417,000 | 1,294,000 |
| Q1 2020 | 4,057,000 | 3,541,000 |
| Q2 2020 | 8,433,000 | 5,652,000 |
| Q3 2020 | 7,025,000 | 5,760,000 |
| Q4 2020 | 6,321,000 | 6,353,000 |
| Q1 2021 | 7,277,000 | 5,279,000 |
| Q2 2021 | 3,769,000 | 3,134,000 |
| Q3 2021 | 3,373,000 | 2,324,000 |
| Q4 2021 | 2,750,000 | 1,387,000 |
| Q1 2022 | 3,338,000 | 657,000 |